PLYX (Polaryx Therapeutics) 5-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PLYX Polaryx Therapeutics Inc PLYX
13 GF Score
Price $2.06
View Full Analysis

What is Polaryx Therapeutics 5-Year EBITDA Growth Rate?

Polaryx Therapeutics PLYX -1.44% 13 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates PLYX with a GF Score™ of 13/100.

Polaryx Therapeutics's EBITDA per Share for the three months ended in Jun. 2026 was $-0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Polaryx Therapeutics  (NAS:PLYX) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Polaryx Therapeutics 5-Year EBITDA Growth Rate Related Terms

PLYX vs BDTX, ENTX, ICCC: 5-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Polaryx Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Polaryx Therapeutics 5-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Polaryx Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Polaryx Therapeutics's 5-Year EBITDA Growth Rate falls into.


PLYX
13GF Score
Polaryx Therapeutics Inc PLYX
5-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Polaryx Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 0.00% mean?
Polaryx Therapeutics (PLYX) has a 5-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Polaryx Therapeutics and its competitors.
Is Polaryx Therapeutics' 5-Year EBITDA Growth Rate too high?
Polaryx Therapeutics' current 5-Year EBITDA Growth Rate is 0.00%. Overall, Polaryx Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Polaryx Therapeutics' 5-Year EBITDA Growth Rate compare to BDTX and ENTX?
Polaryx Therapeutics' 5-Year EBITDA Growth Rate of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Biotechnology company?
A good 5-Year EBITDA Growth Rate depends on the Biotechnology industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Polaryx Therapeutics and its competitors. Polaryx Therapeutics's current 5-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Polaryx Therapeutics stock overvalued right now?
Polaryx Therapeutics (PLYX) has a current 5-Year EBITDA Growth Rate of 0.00%. The current 5-Year EBITDA Growth Rate is 0.00%. Polaryx Therapeutics' overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Polaryx Therapeutics (PLYX), the current 5-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Polaryx Therapeutics Business Description

Other Exchanges 1V8:Germany
Address South Tower, 140 East Ridgewood Avenue, Suite 415, Paramus, NJ, USA, 07652
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
13GF Score

Get the complete analysis for PLYX

5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.06
Price